Expect Integrase Inhibitors to Gain an Edge in Treating HIV
October 2018
Updated guidelines will lead to a shift in preferred antiretroviral meds for treating HIV in adults.
Expect to see more HIV patients admitted on a regimen that includes integrase inhibitors...especially bictegravir (Biktarvy) or dolutegravir (Tivicay, etc) since they seem less likely to develop resistance.
That's because integrase inhibitors are often better tolerated than protease inhibitors, such as darunavir (Prezista, etc)...or NON-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz (Sustiva, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote